Despite some vocal attacks against vaccines, a poll conducted by Republican pollsters — including Donald Trump’s chief pollster — shows “that there is broad unity across party lines supporting vaccines such as measles (MMR), shingles, tetanus, diphtheria and pertussis (TDAP), and Hepatitis B.” NBC News reported that the poll results were made known to Republican…
ACIP’s COVID vaccine workgroup to be headed by vaccine skeptic Retsef Levi
The U.S. Centers for Disease Control and Prevention chose Retsef Levi, a management and health analytics expert at MIT, to lead its COVID-19 immunization workgroup. Levi announced on X that he is “looking forward to working with colleagues… to pursue the truth through science and evidence-based approach.” Levi, one of the eight new ACIP members…
Moderna shares R&D updates at third annual vaccines day
Moderna (Nasdaq:MRNA) recently announced that an investigational version of its COVID-19 vaccine for potential use in children 6 months to 6 years met its primary endpoint in a Phase 2/3 study. Two doses of the vaccine were 43.7% effective at preventing infection during the omicron wave in children aged 6 months to 2 years old.…
CureVac and GSK launch Phase 1 trial of mRNA-based flu vaccine
CureVac (NSDQ:CVAC) and GSK (NYSE:GSK) have announced the dosing of the first participant in a Phase 1 study of a multivalent influenza vaccine built on a second-generation mRNA backbone. The study is based in Panama and will enroll approximately 240 subjects. CVAC shares increased 2.27% to $19.34 in mid-day trading. At various points last year,…
Intranasal FluGen vaccine offers protection in human challenge study
Madison, Wis.–based FluGen has announced that its Bris2007 M2SR flu vaccine candidate demonstrated protection against a multi-seasonal, seven-year drifted influenza strain in a Phase 2 study. Some 54% of M2SR vaccine recipients were infected after exposure to a flu strain. Conversely, 71% of placebo recipients were infected, indicating that the vaccine was 24% effective against…
New therapy could protect lung function in COVID-19 and flu patients
One of the most dangerous aspects of the novel coronavirus is its potential to cause pneumonia and acute respiratory distress syndrome (ARDS). Pandemic influenza A (H1N1) can cause similar problems. A team of researchers at Ohio State University has developed a potential treatment for ARDS stemming from COVID-19 or influenza. The inspiration for the therapy,…